What Is 17β-Estradiol 3-sulfate

Overview

17β-Estradiol 3-sulfate is a conjugated metabolite of the primary female sex hormone, 17β-estradiol. It plays a critical role in estrogen metabolism and regulation, primarily serving as an inactive storage form that can be reactivated in target tissues.

This compound is produced in the liver and circulates in the bloodstream at measurable concentrations. Its formation and breakdown are tightly regulated processes involving specific enzymes and transporters, contributing to overall hormonal balance.

• Chemical structure: 17β-Estradiol 3-sulfate features a sulfate group attached at the C3 position, increasing water solubility and reducing receptor binding affinity compared to free estradiol.
• Discovery timeline: First isolated and characterized in human plasma in 1974 by researchers studying estrogen metabolites using mass spectrometry and chromatography.
• Biological role: Acts as a reservoir for active estrogen; tissues expressing steroid sulfatase can convert it back to bioactive 17β-estradiol when needed.
• Metabolic pathway: Formed during phase II metabolism in the liver, where sulfotransferase enzymes add sulfate groups to steroid hormones for excretion or transport.
• Concentration levels: In adult women, serum levels range from 50 to 200 pg/mL during the follicular phase, increasing slightly during pregnancy.

How It Works

The biological activity of 17β-estradiol 3-sulfate depends on enzymatic interconversion between its sulfated and free forms. While inactive in circulation, it can be hydrolyzed to active estradiol in estrogen-responsive tissues.

• Sulfation:SULT1E1 enzyme in the liver catalyzes sulfate addition to estradiol, with a Km of ~5 nM, making it highly efficient even at low substrate concentrations.
• Transport: The sulfated form is more water-soluble, allowing efficient transport in blood via albumin and other plasma proteins without cellular uptake.
• Receptor binding: 17β-Estradiol 3-sulfate has less than 1% affinity for estrogen receptors ERα and ERβ compared to unconjugated estradiol, rendering it biologically inert.
• Reactivation: In tissues like breast, endometrium, and bone, steroid sulfatase removes the sulfate group, regenerating active estradiol locally.
• Clearance: Due to its polarity, it is primarily excreted in urine, with a plasma half-life of approximately 12–18 hours in healthy adults.
• Regulation: Expression of SULT1E1 and sulfatase enzymes is hormonally regulated, with estrogen itself modulating their transcription in a feedback loop.

Key Comparison

This comparison highlights how structural differences, especially stereochemistry and sulfation position, influence biological activity and pharmacokinetics. 17β-Estradiol 3-sulfate occupies a middle ground—highly stable in circulation but capable of local reactivation, unlike permanently inactivated metabolites.

Key Facts

Understanding the biochemical and physiological properties of 17β-estradiol 3-sulfate provides insight into estrogen dynamics and tissue-specific hormone delivery. Its role extends beyond simple excretion, influencing local estrogen availability.

• Enzyme specificity: SULT1E1 has a Km of 5 nM for estradiol, indicating high affinity and efficiency in sulfation under physiological concentrations.
• Tissue expression: Steroid sulfatase is expressed in over 80% of breast cancers, enabling local estrogen production from sulfated precursors.
• Pregnancy levels: Maternal serum concentrations rise to 300–500 pg/mL in the third trimester due to increased estrogen synthesis.
• Genetic variation: Polymorphisms in the SULT1E1 gene affect enzyme activity, with some variants showing up to 40% reduced function.
• Drug interactions: Certain medications like probenecid inhibit organic anion transporters, potentially altering 17β-estradiol 3-sulfate clearance.
• Research use: Radiolabeled forms (e.g., ³H-estradiol 3-sulfate) are used to study sulfatase activity in tumor biopsies since the 1990s.

Why It Matters

The reversible sulfation of estradiol is crucial for maintaining hormonal balance and enabling localized estrogen action without systemic exposure. This mechanism is especially important in reproductive and bone health.

• Cancer therapy: Inhibiting steroid sulfatase is a strategy in hormone-dependent breast cancer treatment, blocking local estrogen regeneration from precursors like 17β-estradiol 3-sulfate.
• Drug development: Sulfatase inhibitors such as STX64 have entered clinical trials, showing up to 95% enzyme suppression in phase I studies.
• Endocrine disruption: Environmental chemicals may interfere with sulfotransferase or sulfatase activity, potentially altering estrogen homeostasis and contributing to disease.
• Diagnostics: Serum levels of sulfated estrogens are used as biomarkers in assessing ovarian function and fetal-placental health during pregnancy.
• Therapeutic monitoring: Measuring 17β-estradiol 3-sulfate helps evaluate liver metabolism efficiency and the impact of hormonal therapies.

By serving as a dynamic reservoir rather than a terminal metabolite, 17β-estradiol 3-sulfate exemplifies the complexity of steroid hormone regulation. Its study continues to inform endocrinology, oncology, and pharmacology.